-
CSPC Pharmaceutical Gets NMPA Greenlight for SYH2039 Clinical Study in Advanced Malignant Tumors
•
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for its Category 1 chemical drug candidate, SYH2039, which targets advanced malignant tumors. SYH2039 is a potent inhibitor of methionine adenosine…
-
Novo Nordisk Invests RMB 4 Billion to Expand Sterile Manufacturing in Tianjin
•
Novo Nordisk (NYSE: NVO), a Denmark-based leader in diabetes care, has announced a substantial investment of RMB 4 billion (USD 555.6 million) for the expansion of its sterile preparation manufacturing facility in Tianjin. Construction on the site has commenced, with completion expected by 2027. This strategic expansion is set to…
-
Suzhou Porton Biologics Partners with Kunshi Biotech to Advance Third-Generation CAR-M Therapy
•
Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic partnership with Kunshi Biotechnology (Shenzhen) Co., Ltd. The collaboration aims to expedite the Investigational New Drug (IND) filing for Kunshi’s drug candidate RR-M01, marking a significant step forward in the development of third-generation…
-
China Expands Medical Service Pricing Reform with Three Additional Pilot Provinces
•
The National Healthcare Security Administration (NHSA) has announced an expansion of its medical services pricing reform initiative, designating Inner Mongolia, Zhejiang, and Sichuan provinces as pilot regions to further deepen the reform of medical service pricing. These provinces join the existing pilot cities of Tangshan in Hebei, Suzhou in Jiangsu,…
-
Swiss Pharma Firm Carbogen Amcis Receives Brazil’s ANVISA GMP Certification for Shanghai Site
•
Carbogen Amcis, a Swiss firm specializing in active pharmaceutical ingredients (APIs) and pharmaceutical process development, has announced that its Shanghai facility has successfully passed its inaugural routine inspection by Brazil’s National Health Surveillance Agency (ANVISA). The five-day inspection in November 2023 has resulted in the site being awarded Good Manufacturing…
-
Everest Medicines Strengthens Leadership with Appointments of Sandra Zeng and Rico Liang
•
Everest Medicines (HKG: 1952), a leading China-based biotechnology company, has announced two significant appointments to its senior management team. Sandra Zeng has been named Chief Medical Officer, and Rico Liang has been appointed as Chief Product Officer. These strategic hires are set to bolster the company’s drug development and product…
-
WuXi XDC Breaks Ground on State-of-the-Art Manufacturing Base in Singapore to Boost ADC Production
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced plans to construct a new manufacturing base at the Tuas Biomedical Park in Singapore. This strategic expansion is designed to enhance the joint venture’s…
-
Shanghai Winpu Technology and Silver Mars Merge Under YinKe Holding to Accelerate Healthcare Innovation
•
Shanghai Winpu Technology Co., Ltd., a specialist in medical-grade polymer materials based in China, has announced a strategic merger with Silver Mars, a Suzhou-based high-tech firm specializing in bionic materials. The merged entity falls under the umbrella of YinKe Holding, a technology conglomerate with a focus on the healthcare sector.…
